Kyoto Prefectural University of Medicine · Faculty of Medicine · 准教授

Research keywordsRB-reactivator screening・cancer prevention・MEK inhibitor・GGCT・EGFR・ALK・molecular targeted therapy・drug resistance

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Discovery of cancer-preventive juices reactivating RB functions. Masuda M, Horinaka M, Yasuda S, Morita M, Nishimoto E, Ishikawa H, Mutoh M, Sakai T. Environ Health Prev Med. 2023; 28:2023
• “RB-reactivator screening” as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). Sakai T. Pharmacol Ther. 2022; 236: 108234. 3)Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, C1991
• KRAS-G12C陽性肺がんにおけるAXLの活性化を介したKRAS-G12C阻害薬初期治療抵抗性(Adaptive resistance to KRAS-G12C inhibitors through AXL activation in KRAS-G12C mutant tumor cells)
• Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.

• RB失活難治性がんに対する先制医療の開発
• ヘビの防御物質ブファジエノライド：食性進化のメカニズム解明
• TRAIL経路活性化による糖尿病患者のための分子標的癌予防法の開発
• 骨肉腫に対する新規分子標的併用療法の開発

• Official profile